ALVR - Kirby McInerney LLP Reminds Investors of Lead Plaintiff Deadline in AlloVir Inc. (ALVR) Securities Class Action | Benzinga

NEW YORK, Feb. 23, 2024 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors of the March 19, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed on behalf of those who acquired AlloVir, Inc. ("AlloVir" or the "Company") (NASDAQ:ALVR) securities during the period of March 22, 2022 through December 21, 2023, inclusive ("the Class Period").

[Click here to learn more about the class action]

In March 2022, AlloVir initiated global phase 3 registrational studies of its lead product posoleucel for the prevention of life-threatening viral infections from viruses in high-risk, allogeneic hematopoietic cell transplant patients (the "posoleucel Phase 3 ...

ALVR) Securities Class Action>Full story available on Benzinga.com